Symbols / MGTX Stock $9.97 +1.84% MeiraGTx Holdings plc

Healthcare • Biotechnology • United States • NMS
MGTX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Alexandria Forbes Ph.D.
Exch · Country NMS · United States
Market Cap 922.96M
Enterprise Value 834.77M
Income -114.20M
Sales 81.39M
FCF (ttm) -10.01M
Book/sh -0.07
Cash/sh 0.81
Employees 400
Insider 10d —
IPO Jun 08, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -6.57
PEG —
P/S 11.34
P/B -140.42
P/C —
EV/EBITDA -8.94
EV/Sales 10.26
Quick Ratio 0.69
Current Ratio 0.75
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -1.42
EPS next Y -1.52
EPS Growth —
Revenue Growth 252.30%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-14
Earnings (prior) 2026-03-26
ROA -25.76%
ROE -3.68%
ROIC —
Gross Margin 94.05%
Oper. Margin 35.13%
Profit Margin -140.31%
Shs Outstand 92.57M
Shs Float 46.68M
Insider Own 17.88%
Instit Own 57.64%
Short Float 8.77%
Short Ratio 5.09
Short Interest 5.73M
52W High 11.85
vs 52W High -15.86%
52W Low 4.55
vs 52W Low 119.12%
Beta 1.24
Impl. Vol. 4.96%
Rel Volume 0.51
Avg Volume 694.11K
Volume 356.36K
Target (mean) $27.88
Tgt Median $25.50
Tgt Low $18.00
Tgt High $50.00
# Analysts 8
Recom None
Prev Close $9.79
Price $9.97
Change 1.84%
About

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$27.88
Mean price target
2. Current target
$9.97
Latest analyst target
3. DCF / Fair value
$-1.95
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$9.97
Low
$18.00
High
$50.00
Mean
$27.88

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-22 main Piper Sandler Overweight → Overweight $30
2026-04-17 main RBC Capital Outperform → Outperform $24
2026-04-01 main Evercore ISI Group Outperform → Outperform $18
2026-03-27 main Piper Sandler Overweight → Overweight $26
2026-03-27 main B of A Securities Buy → Buy $16
2026-03-27 main Chardan Capital Buy → Buy $35
2025-11-24 init HC Wainwright & Co. — → Buy $20
2025-11-14 main RBC Capital Outperform → Outperform $16
2025-11-14 main Chardan Capital Buy → Buy $35
2025-11-11 main Piper Sandler Overweight → Overweight $30
2025-11-11 main Chardan Capital Buy → Buy $35
2025-10-21 init Raymond James — → Strong Buy $29
2025-08-15 main Chardan Capital Buy → Buy $35
2025-05-14 main Chardan Capital Buy → Buy $35
2025-03-17 main RBC Capital Outperform → Outperform $13
2025-02-24 main Chardan Capital Buy → Buy $36
2024-11-18 main Chardan Capital Buy → Buy $36
2024-11-14 main RBC Capital Outperform → Outperform $11
2024-08-13 main RBC Capital Outperform → Outperform $9
2024-07-31 main Chardan Capital Buy → Buy $36
News
RSS: Latest MGTX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-21 GIROUX RICHARD Chief Operating Officer — 56,000 $10.22 $572,320
2026-04-17 PERCEPTIVE ADVISORS, L.L.C. Beneficial Owner of more than 10% of a Class of Security — 555,555 $9.00 $4,999,995
2026-04-07 NAYLOR STUART Officer — 27,661 $9.36 $258,907
2026-03-24 FORBES ALEXANDRIA Chief Executive Officer — 62,000 $7.41 $459,420
2026-02-20 FORBES ALEXANDRIA Chief Executive Officer — 62,500 — —
2026-02-20 ZELDIN ROBERT K Officer — 7,500 — —
2026-02-20 GIROUX RICHARD Chief Operating Officer — 60,000 — —
2026-02-20 NAYLOR STUART Officer — 25,000 — —
2026-02-20 WOLLIN ROBERT J General Counsel — 11,250 — —
2026-01-16 FORBES ALEXANDRIA Chief Executive Officer — 310,000 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
81.39
+144.57%
33.28
+137.42%
14.02
-11.95%
15.92
Operating Revenue
81.39
+144.57%
33.28
+137.42%
14.02
-11.95%
15.92
Cost Of Revenue
4.84
-79.64%
23.79
0.00
—
Reconciled Cost Of Revenue
4.84
-79.64%
23.79
0.00
—
Gross Profit
76.55
+706.79%
9.49
-32.31%
14.02
—
Operating Expense
182.52
+5.08%
173.70
+14.97%
151.08
+14.22%
132.28
Research And Development
129.62
+8.48%
119.48
+15.13%
103.78
+21.07%
85.72
Selling General And Administration
52.90
-2.43%
54.22
+14.64%
47.29
+1.60%
46.55
General And Administrative Expense
52.90
-2.43%
54.22
+14.64%
47.29
+1.60%
46.55
Other Gand A
52.90
-2.43%
54.22
+14.64%
47.29
+1.60%
46.55
Total Expenses
187.36
-5.13%
197.49
+30.72%
151.08
+14.22%
132.28
Operating Income
-105.97
+35.47%
-164.21
-19.81%
-137.06
-17.80%
-116.36
Total Operating Income As Reported
-105.97
+35.47%
-164.21
-19.81%
-137.06
-17.80%
-116.36
EBITDA
-89.40
+26.63%
-121.84
-113.53%
-57.06
+50.84%
-116.07
Normalized EBITDA
-91.54
+37.89%
-147.39
-22.25%
-120.57
-12.70%
-106.97
Reconciled Depreciation
12.61
-0.59%
12.68
-7.60%
13.72
+59.53%
8.60
EBIT
-102.00
+24.17%
-134.52
-90.05%
-70.78
+43.22%
-124.67
Total Unusual Items
2.15
-91.60%
25.55
-59.77%
63.51
+798.58%
-9.09
Total Unusual Items Excluding Goodwill
2.15
-91.60%
25.55
-59.77%
63.51
+798.58%
-9.09
Special Income Charges
0.00
-100.00%
28.43
-47.55%
54.21
0.00
Net Income
-114.20
+22.73%
-147.79
-75.89%
-84.03
+35.17%
-129.62
Pretax Income
-114.20
+22.73%
-147.79
-75.89%
-84.03
+35.17%
-129.62
Net Non Operating Interest Income Expense
-10.38
-13.72%
-9.13
+16.82%
-10.97
-163.20%
-4.17
Interest Expense Non Operating
12.20
-8.10%
13.27
+0.20%
13.24
+167.79%
4.95
Net Interest Income
-10.38
-13.72%
-9.13
+16.82%
-10.97
-163.20%
-4.17
Interest Expense
12.20
-8.10%
13.27
+0.20%
13.24
+167.79%
4.95
Interest Income Non Operating
1.82
-56.14%
4.14
+82.44%
2.27
+192.41%
0.78
Interest Income
1.82
-56.14%
4.14
+82.44%
2.27
+192.41%
0.78
Other Income Expense
2.15
-91.60%
25.55
-60.09%
64.01
+804.07%
-9.09
Other Non Operating Income Expenses
—
—
0.50
+38.23%
0.36
Gain On Sale Of Security
2.15
+174.36%
-2.89
-131.03%
9.30
+202.30%
-9.09
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-114.20
+22.73%
-147.79
-75.89%
-84.03
+35.17%
-129.62
Net Income From Continuing Operation Net Minority Interest
-114.20
+22.73%
-147.79
-75.89%
-84.03
+35.17%
-129.62
Net Income From Continuing And Discontinued Operation
-114.20
+22.73%
-147.79
-75.89%
-84.03
+35.17%
-129.62
Net Income Continuous Operations
-114.20
+22.73%
-147.79
-75.89%
-84.03
+35.17%
-129.62
Normalized Income
-116.35
+32.88%
-173.34
-17.49%
-147.53
-22.41%
-120.52
Net Income Common Stockholders
-114.20
+22.73%
-147.79
-75.89%
-84.03
+35.17%
-129.62
Diluted EPS
-1.42
+33.02%
-2.12
-42.28%
-1.49
+48.08%
-2.87
Basic EPS
-1.42
+33.02%
-2.12
-42.28%
-1.49
+48.08%
-2.87
Basic Average Shares
80.43
+15.19%
69.82
+23.61%
56.49
+25.03%
45.18
Diluted Average Shares
80.43
+15.19%
69.82
+23.61%
56.49
+25.03%
45.18
Diluted NI Availto Com Stockholders
-114.20
+22.73%
-147.79
-75.89%
-84.03
+35.17%
-129.62
Gain On Sale Of PPE
0.00
-100.00%
28.43
-47.55%
54.21
0.00
Line Item Trend 2023-12-31
Total Assets
326.74
Current Assets
159.62
Cash Cash Equivalents And Short Term Investments
129.57
Cash And Cash Equivalents
129.57
Receivables
23.41
Accounts Receivable
10.14
Other Receivables
—
Taxes Receivable
13.28
Inventory
0.00
Prepaid Assets
5.62
Other Current Assets
1.02
Total Non Current Assets
167.12
Net PPE
156.24
Gross PPE
189.56
Accumulated Depreciation
-33.33
Properties
0.00
Machinery Furniture Equipment
8.10
Other Properties
78.38
Leases
103.08
Goodwill And Other Intangible Assets
1.12
Other Intangible Assets
1.12
Investments And Advances
6.77
Long Term Equity Investment
6.77
Other Non Current Assets
3.00
Total Liabilities Net Minority Interest
188.57
Current Liabilities
67.08
Payables And Accrued Expenses
46.55
Payables
16.04
Accounts Payable
16.04
Current Accrued Expenses
30.51
Pensionand Other Post Retirement Benefit Plans Current
12.13
Current Debt And Capital Lease Obligation
4.19
Current Debt
—
Other Current Borrowings
—
Current Capital Lease Obligation
4.19
Current Deferred Liabilities
2.93
Current Deferred Revenue
2.93
Other Current Liabilities
1.28
Total Non Current Liabilities Net Minority Interest
121.49
Long Term Debt And Capital Lease Obligation
85.07
Long Term Debt
72.12
Long Term Capital Lease Obligation
12.95
Long Term Provisions
2.40
Non Current Deferred Liabilities
34.02
Non Current Deferred Revenue
34.02
Non Current Deferred Taxes Liabilities
0.00
Other Non Current Liabilities
—
Stockholders Equity
138.18
Common Stock Equity
138.18
Capital Stock
0.00
Common Stock
0.00
Share Issued
63.60
Ordinary Shares Number
63.60
Treasury Shares Number
0.00
Additional Paid In Capital
693.84
Retained Earnings
-554.23
Gains Losses Not Affecting Retained Earnings
-1.44
Other Equity Adjustments
-1.44
Total Equity Gross Minority Interest
138.18
Total Capitalization
210.30
Working Capital
92.54
Invested Capital
210.30
Total Debt
89.26
Net Debt
—
Capital Lease Obligations
17.14
Net Tangible Assets
137.06
Tangible Book Value
137.06
Interest Payable
2.94
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-46.36
+55.64%
-104.50
+0.83%
-105.36
-44.14%
-73.10
Cash Flow From Continuing Operating Activities
-46.30
+55.76%
-104.64
+0.69%
-105.37
-43.91%
-73.22
Net Income From Continuing Operations
-114.20
+22.73%
-147.79
-75.89%
-84.03
+35.17%
-129.62
Depreciation Amortization Depletion
12.61
-0.59%
12.68
-7.60%
13.72
+59.53%
8.60
Depreciation
12.31
-0.61%
12.38
-7.77%
13.42
+59.75%
8.40
Amortization Cash Flow
0.30
+0.00%
0.30
+0.00%
0.30
+50.00%
0.20
Depreciation And Amortization
12.61
-0.59%
12.68
-7.60%
13.72
+59.53%
8.60
Amortization Of Intangibles
0.30
+0.00%
0.30
+0.00%
0.30
+50.00%
0.20
Other Non Cash Items
6.89
+30.17%
5.29
+871.19%
0.55
+150.00%
0.22
Stock Based Compensation
22.11
-12.25%
25.19
-9.11%
27.72
-3.17%
28.62
Asset Impairment Charge
—
0.00
-100.00%
1.15
0.00
Operating Gains Losses
-1.79
+92.98%
-25.52
+59.80%
-63.49
-771.70%
9.45
Net Foreign Currency Exchange Gain Loss
-2.15
-174.36%
2.89
+131.03%
-9.30
-198.39%
9.45
Gain Loss On Sale Of PPE
0.35
+3844.44%
0.01
+100.02%
-54.20
0.00
Change In Working Capital
28.03
+9.27%
25.65
+2709.66%
-0.98
-110.22%
9.62
Change In Receivables
-7.27
-177.10%
9.43
+95.28%
4.83
-6.65%
5.17
Changes In Account Receivables
-2.34
-136.95%
6.33
-36.59%
9.97
+866.57%
1.03
Change In Inventory
0.43
+210.59%
-0.39
0.00
—
Change In Prepaid Assets
0.72
+154.22%
-1.33
-149.37%
2.69
+917.63%
-0.33
Change In Payables And Accrued Expense
-7.90
-145.39%
-3.22
-265.35%
1.95
-88.08%
16.35
Change In Accrued Expense
4.41
+131.59%
-13.96
-3554.19%
-0.38
-103.03%
12.61
Change In Payable
-12.31
-214.67%
10.74
+360.86%
2.33
-37.65%
3.74
Change In Account Payable
-12.31
-214.67%
10.74
+360.86%
2.33
-37.65%
3.74
Change In Other Working Capital
-0.73
-102.74%
26.66
+455.24%
-7.51
+52.85%
-15.92
Change In Other Current Assets
-0.52
+66.04%
-1.54
+2.77%
-1.59
-558.67%
0.35
Change In Other Current Liabilities
43.31
+1194.24%
-3.96
-192.10%
-1.35
-133.82%
4.01
Investing Cash Flow
-4.11
-117.49%
23.48
-31.01%
34.03
+175.69%
-44.96
Cash Flow From Continuing Investing Activities
-4.11
-117.49%
23.48
-31.01%
34.03
+175.69%
-44.96
Net PPE Purchase And Sale
-3.70
+25.39%
-4.96
+75.44%
-20.17
+55.13%
-44.96
Purchase Of PPE
-3.83
+22.79%
-4.96
+75.44%
-20.17
+55.13%
-44.96
Sale Of PPE
0.13
0.00
—
—
Capital Expenditure
-4.24
+14.51%
-4.96
+75.44%
-20.17
+55.13%
-44.96
Net Business Purchase And Sale
—
—
—
0.00
Purchase Of Business
—
—
—
0.00
Net Intangibles Purchase And Sale
-0.41
0.00
-100.00%
54.21
0.00
Purchase Of Intangibles
-0.41
0.00
—
—
Net Other Investing Changes
—
28.43
-47.55%
54.21
—
Financing Cash Flow
12.27
-77.50%
54.53
-35.10%
84.02
-11.74%
95.20
Cash Flow From Continuing Financing Activities
12.27
-77.50%
54.53
-35.10%
84.02
-11.74%
95.20
Net Issuance Payments Of Debt
-0.03
0.00
0.00
-100.00%
75.00
Issuance Of Debt
—
—
0.00
-100.00%
75.00
Repayment Of Debt
-0.03
0.00
—
0.00
Long Term Debt Issuance
—
—
—
75.00
Long Term Debt Payments
-0.03
0.00
—
0.00
Net Long Term Debt Issuance
-0.03
0.00
—
75.00
Short Term Debt Issuance
—
—
0.00
-100.00%
75.00
Net Short Term Debt Issuance
—
—
0.00
-100.00%
75.00
Net Common Stock Issuance
15.07
-74.62%
59.39
-35.41%
91.95
+267.80%
25.00
Cash Dividends Paid
—
—
—
0.00
Proceeds From Stock Option Exercised
0.26
0.00
-100.00%
0.01
-95.67%
0.23
Net Other Financing Charges
-3.03
+37.60%
-4.86
+38.82%
-7.94
-57.76%
-5.03
Changes In Cash
-38.19
-44.23%
-26.48
-308.65%
12.69
+155.52%
-22.86
Effect Of Exchange Rate Changes
0.72
-52.10%
1.50
-38.51%
2.44
+262.17%
0.67
Beginning Cash Position
105.67
-19.12%
130.65
+13.10%
115.52
-16.11%
137.70
End Cash Position
68.19
-35.46%
105.67
-19.12%
130.65
+13.10%
115.52
Free Cash Flow
-50.59
+53.77%
-109.45
+12.82%
-125.54
-6.33%
-118.06
Interest Paid Supplemental Data
11.04
-8.26%
12.03
-7.85%
13.05
+3867.78%
0.33
Common Stock Issuance
15.07
-74.62%
59.39
-35.41%
91.95
+267.80%
25.00
Earnings Losses From Equity Investments
0.00
-100.00%
0.02
+183.33%
0.01
0.00
Interest Paid CFF
—
—
—
-2.26
Issuance Of Capital Stock
15.07
-74.62%
59.39
-35.41%
91.95
+267.80%
25.00
Sale Of Intangibles
—
—
54.21
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category